Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNETISMM-6
2021-000803-20Phase 3Active
- Sponsor
- Pfizer
- Start
- Oct 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of elranatamab in multiple myeloma (MM) (2 arms), sponsored by Pfizer. Started Oct 2022; status: active.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-000803-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000803-20.